🔗 Share this article

Given that the US proceeds with unprecedented changes to its vaccine recommendations, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent physician and public health researcher who first made her name by expressing skepticism about coronavirus vaccines throughout the global health crisis and has zeroed in on potential deaths following COVID-19 vaccination in her recent tenure at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Schedule

Public health authorities had intended to unveil major revisions to the childhood vaccine schedule in December, aligning the US with the Danish national calendar, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with no evidence for public health gain. The planned update has been pushed back until the coming year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to present at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the office this year.

A New Direction at the FDA

Høeg's temporary position might represent a closer partnership between the drug and biologics centers as Høeg and Dr. Prasad strengthen their influence at the agency – and it suggests a renewed priority upon rolling back already-approved vaccines at the FDA.

The new acting director has frequently advocated for discontinuing specific childhood vaccine recommendations in the US so as to align more similar to Denmark, a society with nationalized medicine and a number of inhabitants about the size of the state of Wisconsin.

In her initial statements, she has persisted in emphasizing on immunizations – traditionally the responsibility of Dr. Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Questions Over Background

Høeg has little discernible background in drug development, regulation or management, which has been typical for previous heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since spring.

“She appears not to have the necessary background” for running the pharmaceutical oversight division, said a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in managing a large organization. She lacks background in industry regulation.”

Previous commissioners of CBER would “grasp laws and regulations and the science of pharmaceutical innovation”, commented a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that former directors who ran the center have had.”

The drug center has an enormous workload at the FDA, the former commissioner pointed out.

“The public just zeroes in on the innovative therapies, but the generic drug division clears a multitude of generic drugs. There’s a biosimilars division, over-the-counter program and more, and every single one need to be managed,” Woodcock said. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Furthermore, a major leadership element to the role, which oversees in excess of 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” Woodcock concluded.

Agency Reaction and Contentious Initiatives

In response to questions about Høeg’s fitness for the role and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a spokesperson said that the “concerns rely on flawed assumptions”.

“Her experience matches the duties of her position,” the official explained, citing the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s new priority voucher program, a contentious one-day therapy clearance system that reportedly concerned her preceding directors. “By what process are these medications being selected for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of lack of transparency occurring at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent regulations of all drugs, except for immunizations.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more established, if concerning, history, Howard said. She authored a study using non-validated crowd-sourced reports to assess the incidence of heart inflammation following Covid vaccination. She consulted for the Florida chief medical officer Joseph Ladapo, who was said to have altered data to indicate COVID-19 vaccinations are riskier than they are.

Part of her “policy goals” for the incoming government encompassed revising guidelines for new vaccines and halting “non-essential” vaccines, she said post-election on a online show. At the agency, Dr. Høeg has reportedly suggested excluding teenage boys from getting COVID-19 vaccines.

“She is an all-around ideologue who commences with her conclusions and tailors the evidence to accommodate the science in a extremely misleading, dishonest fashion,” Howard argued.

Taking Control and a “Campaign of Retribution”

Høeg aligned with other dissenters, {like|